SK282250B6 - Deriváty 4,9-etanobenzo[f]izoindolu, spôsob ich prípravy a farmaceutické kompozície obsahujúce tieto deriváty - Google Patents

Deriváty 4,9-etanobenzo[f]izoindolu, spôsob ich prípravy a farmaceutické kompozície obsahujúce tieto deriváty Download PDF

Info

Publication number
SK282250B6
SK282250B6 SK26-98A SK2698A SK282250B6 SK 282250 B6 SK282250 B6 SK 282250B6 SK 2698 A SK2698 A SK 2698A SK 282250 B6 SK282250 B6 SK 282250B6
Authority
SK
Slovakia
Prior art keywords
group
phenyl
mmol
ethano
hexahydro
Prior art date
Application number
SK26-98A
Other languages
English (en)
Slovak (sk)
Other versions
SK2698A3 (en
Inventor
Alain Commercon
Brun Alain Le
Patrick Mailliet
Jean-Francois Peyronel
Fabienne Sounigo-Thompson
Alain Truchon
Martine Zucco
Original Assignee
Rhone-Poulenc Rorer S. A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone-Poulenc Rorer S. A. filed Critical Rhone-Poulenc Rorer S. A.
Publication of SK2698A3 publication Critical patent/SK2698A3/sk
Publication of SK282250B6 publication Critical patent/SK282250B6/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/724,7-Endo-alkylene-iso-indoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings
    • C07F9/5728Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK26-98A 1995-07-10 1996-07-08 Deriváty 4,9-etanobenzo[f]izoindolu, spôsob ich prípravy a farmaceutické kompozície obsahujúce tieto deriváty SK282250B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9508296A FR2736641B1 (fr) 1995-07-10 1995-07-10 Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
PCT/FR1996/001062 WO1997003050A1 (fr) 1995-07-10 1996-07-08 DERIVES DE 4,9-ETHANO-BANZO(f)ISOINDOLE COMME INHIBITEURS DE FARNESYL TRANSFERASE

Publications (2)

Publication Number Publication Date
SK2698A3 SK2698A3 (en) 1998-07-08
SK282250B6 true SK282250B6 (sk) 2001-12-03

Family

ID=9480830

Family Applications (1)

Application Number Title Priority Date Filing Date
SK26-98A SK282250B6 (sk) 1995-07-10 1996-07-08 Deriváty 4,9-etanobenzo[f]izoindolu, spôsob ich prípravy a farmaceutické kompozície obsahujúce tieto deriváty

Country Status (32)

Country Link
US (1) US5936097A (es)
EP (1) EP0839133B1 (es)
JP (1) JPH11511123A (es)
KR (1) KR19990028856A (es)
CN (1) CN1096448C (es)
AR (1) AR003143A1 (es)
AT (1) ATE185341T1 (es)
AU (1) AU712194B2 (es)
BR (1) BR9609440A (es)
CA (1) CA2224414A1 (es)
CO (1) CO4700457A1 (es)
CZ (1) CZ291620B6 (es)
DE (1) DE69604588T2 (es)
DK (1) DK0839133T3 (es)
EA (1) EA000797B1 (es)
ES (1) ES2139373T3 (es)
FR (1) FR2736641B1 (es)
GR (1) GR3031409T3 (es)
IL (1) IL122812A (es)
MA (1) MA23929A1 (es)
MX (1) MX9800262A (es)
MY (1) MY114792A (es)
NO (1) NO309565B1 (es)
NZ (1) NZ313211A (es)
PE (1) PE11898A1 (es)
PL (1) PL324430A1 (es)
SK (1) SK282250B6 (es)
TN (1) TNSN96098A1 (es)
TW (1) TW438792B (es)
UY (1) UY24276A1 (es)
WO (1) WO1997003050A1 (es)
ZA (1) ZA965868B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757855B1 (fr) * 1996-12-30 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
US6013662A (en) 1996-12-30 2000-01-11 Rhone-Poulenc Rorer S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
US6124465A (en) * 1997-11-25 2000-09-26 Rhone-Poulenc S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
WO1999033834A1 (fr) * 1997-12-23 1999-07-08 Aventis Pharma S.A. Nouveaux inhibiteurs de farnesyle transferase, leur preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour la preparation de medicaments
FR2772764B1 (fr) * 1997-12-23 2000-01-14 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyle transferase, leur preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour la preparation de medicaments
FR2787327B1 (fr) * 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase
FR2796641B1 (fr) 1999-07-22 2001-09-21 Aventis Pharma Sa Nouveau procede de preparation de composes benzoperhydroisoindole
US20020177575A1 (en) * 2001-05-04 2002-11-28 Ward Wakeland Identification of farnesyl-protein transferase as a target for systemic lupus erythematosus therapies
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
PL2109608T3 (pl) 2007-01-10 2011-08-31 Msd Italia Srl Indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy)-(PARP)
WO2008106692A1 (en) 2007-03-01 2008-09-04 Novartis Vaccines And Diagnostics, Inc. Pim kinase inhibitors and methods of their use
KR20100017866A (ko) 2007-05-21 2010-02-16 노파르티스 아게 Csf-1r 억제제, 조성물 및 사용 방법
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8765747B2 (en) 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
CN103080093A (zh) 2010-03-16 2013-05-01 达纳-法伯癌症研究所公司 吲唑化合物及其应用
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CA3186328A1 (en) 2010-07-28 2012-02-02 Janssen Pharmaceutica Nv Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸(siNA)的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1(CTNNB1)基因表达的抑制
SI2606134T1 (sl) 2010-08-17 2019-08-30 Sirna Therapeutics, Inc. RNA-INTERFERENČNO POSREDOVANO ZAVIRANJE IZRAŽANJA GENA VIRUSA HEPATITISA B (HBV) Z UPORABO KRATKE INTERFERENČNE NUKLEINSKE KISLINE (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
IN2013MN02170A (es) 2011-04-21 2015-06-12 Piramal Entpr Ltd
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド C−jun−n−末端キナーゼ(jnk)の阻害剤
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Erk阻害剤である新規化合物
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
PL2925888T3 (pl) 2012-11-28 2018-03-30 Merck Sharp & Dohme Corp. Kompozycje i sposoby do stosowania w leczeniu nowotworów
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015058140A1 (en) 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3057955B1 (en) 2013-10-18 2018-04-11 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
JP6861166B2 (ja) 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド サイクリン依存性キナーゼの阻害剤
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2985123C (en) 2015-08-17 2021-04-13 Antonio Gualberto Methods of treating cancer patients with farnesyltransferase inhibitors
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
MY190861A (en) 2016-11-03 2022-05-12 Kura Oncology Inc Farnesyltransferase inhibitors for use in methods of treating cancer
CN110650976B (zh) 2017-04-13 2024-04-19 赛罗帕私人有限公司 抗SIRPα抗体
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020190604A1 (en) 2019-03-15 2020-09-24 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
EP4303246A1 (de) 2022-07-04 2024-01-10 Covestro Deutschland AG Polyisocyanatgemisch
WO2024180169A1 (en) 2023-03-02 2024-09-06 Carcimun Biotech Gmbh Means and methods for diagnosing cancer and/or an acute inflammatory disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492372A1 (fr) * 1980-10-21 1982-04-23 Cird Dihydroxy-1,8 anthrones-9 substituees en position 10 et leur utilisation en medecine humaine ou veterinaire et en cosmetique
CA2170766A1 (en) * 1993-11-05 1995-05-11 Gary Louis Bolton Substituted di- and tripeptide inhibitors of protein:farnesyl transferase

Also Published As

Publication number Publication date
EA199800118A1 (ru) 1998-08-27
CZ291620B6 (cs) 2003-04-16
MX9800262A (es) 1998-04-30
DK0839133T3 (da) 2000-04-17
PE11898A1 (es) 1998-03-15
TNSN96098A1 (fr) 2005-03-15
EA000797B1 (ru) 2000-04-24
WO1997003050A1 (fr) 1997-01-30
IL122812A (en) 2001-04-30
ZA965868B (en) 1997-01-29
CN1190389A (zh) 1998-08-12
ATE185341T1 (de) 1999-10-15
AU712194B2 (en) 1999-10-28
TW438792B (en) 2001-06-07
JPH11511123A (ja) 1999-09-28
BR9609440A (pt) 1999-06-29
CN1096448C (zh) 2002-12-18
AR003143A1 (es) 1998-07-08
FR2736641B1 (fr) 1997-08-22
NZ313211A (en) 1999-11-29
GR3031409T3 (en) 2000-01-31
CA2224414A1 (fr) 1997-01-30
MY114792A (en) 2003-01-31
KR19990028856A (ko) 1999-04-15
NO980094L (no) 1998-02-17
UY24276A1 (es) 2001-10-25
MA23929A1 (fr) 1997-04-01
CO4700457A1 (es) 1998-12-29
NO980094D0 (no) 1998-01-09
SK2698A3 (en) 1998-07-08
IL122812A0 (en) 1998-08-16
NO309565B1 (no) 2001-02-19
DE69604588T2 (de) 2000-05-18
ES2139373T3 (es) 2000-02-01
FR2736641A1 (fr) 1997-01-17
DE69604588D1 (en) 1999-11-11
EP0839133A1 (fr) 1998-05-06
AU6522496A (en) 1997-02-10
CZ5498A3 (cs) 1998-04-15
PL324430A1 (en) 1998-05-25
EP0839133B1 (fr) 1999-10-06
US5936097A (en) 1999-08-10

Similar Documents

Publication Publication Date Title
SK282250B6 (sk) Deriváty 4,9-etanobenzo[f]izoindolu, spôsob ich prípravy a farmaceutické kompozície obsahujúce tieto deriváty
US5523430A (en) Protein farnesyl transferase inhibitors
CA2344707C (en) N-substituted cycloalkyl and polycycloalkyl alpha-substituted trp-phe- and phenethylamine derivatives
US5389631A (en) Fibrinogen receptor antagonists
JP3529381B2 (ja) エンドテリン変換酵素阻害剤
CA1244041A (en) Process for the preparation of cis, endo- octahydrocyclopenta¬b|pyrrole-2-carboxylate
EP0415487A2 (en) Beta-lactams as anticholesterolemic agents
KR19980703151A (ko) 락탐-함유 히드록삼산 유도체, 그의 제조 그리고 매트릭스 메탈로프로테아제의 억제제로서의 그의 용도
US5210266A (en) N-substituted mercaptopropanamide derivatives
UA75060C2 (en) Substituted n-benzyl-indole-3-yl-glyoxylic acid derivatives having antitumor activity, use thereof and pharmaceutical composition based thereon
US5179125A (en) N-substituted mercaptopropanamide derivatives
FR2755135A1 (fr) Nouveaux derives d'(alpha-aminophosphino)peptides, leur procede de preparation et les compositions qui les contiennent
EP1009770A1 (en) Peptides containing an arginine mimetic for the treatment of bone metabolic disorders, their production, and drugs containing these compounds
CA1329681C (en) N_-(1-carboxy-3-phenylpropyl)-l-lysine derivative and process of producing lysinopril using the compound
WO1998015525A1 (fr) Acides hydroxamiques
US6403561B1 (en) Tripeptidylpeptidase inhibitors
JP2000506120A (ja) ベータ―チオプロピオニル―アミノ酸およびそのベータ―ラクタマーゼ阻害剤としての使用
US5861529A (en) Farnesyl transferase inhibitors, their preparation and the pharmaceutical compositions which contain them
CA2315703C (en) Tripeptidyl peptidase inhibitors
CA2248070A1 (en) Peptidyl compounds having mmp and tnf inhibitory activity
US5194430A (en) Heterocyclic-nmda antagonists
EP0116432A2 (en) Improvements in or relating to N-(substituted-methyl)-azetidin-2-ones
FR2757855A1 (fr) Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
GB2052482A (en) N - acyl - amino acid derivatives
HU188177B (en) Process for producing new proline derivatives